. . . . . . . . . . . . . . "a(SCHEM:\"NS 398\") -| cat(p(HGNC:PTGS2))" . "Approximately 61,000 statements." . "Copyright (c) 2011-2012, Selventa. All rights reserved." . "BEL Framework Large Corpus Document" . . "1.4" . "A COX-2-selective inhibitor, NS-398 (10 µM), was used to determine whether COX-2 was responsible for the observed increases in PGE2 synthesis by CSE-treated fibroblasts (62). Two different strains of human lung fibroblasts were pretreated with NS-398 for 1 h before treatment with 1% CSE for 24 h, and supernatants were analyzed for PGE2. As shown in Fig. 2, the fibroblast strains incubated with 1% CSE had a three- to fourfold induction in PGE2 synthesis over basal levels after 24 h, depending on the strain. However, cells treated with both CSE and NS-398 had significantly decreased PGE2 levels relative to fibroblasts treated with CSE alone, supporting the idea that the elevated PGE2 levels are a result of COX-2 activity. " . . "Selventa" . . . . "2014-07-03T14:30:25.613+02:00"^^ . . .